Compare LMRI & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMRI | CERT |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2025 | 2020 |
| Metric | LMRI | CERT |
|---|---|---|
| Price | $10.70 | $8.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $20.75 | $11.67 |
| AVG Volume (30 Days) | 268.4K | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $6.35 | $4.18 |
| Revenue Next Year | $5.61 | $5.39 |
| P/E Ratio | $213.60 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $6.45 | $4.45 |
| 52 Week High | $19.45 | $13.88 |
| Indicator | LMRI | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 59.66 |
| Support Level | $10.09 | $8.54 |
| Resistance Level | $12.69 | $8.89 |
| Average True Range (ATR) | 0.55 | 0.32 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 0.57 | 96.31 |
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.